symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
HBPCF,0.145,-0.48042,96,30486396,0,0.14-0.18,0,Helix BioPharma Corp.,USD,,,,Other OTC,PNK,Biotechnology,https://www.helixbiopharma.com,"Helix BioPharma Corp. operates as an immune-oncology company in Canada. The company is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.",Mr. Jacek  Antas,Healthcare,CA,7,,401 Bay Street,Toronto,ON,M5H 2Y4,,0,https://financialmodelingprep.com/image-stock/HBPCF.png,2009-11-27,True,False,False,False,False
